CA2362527A1 - A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer - Google Patents
A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer Download PDFInfo
- Publication number
- CA2362527A1 CA2362527A1 CA002362527A CA2362527A CA2362527A1 CA 2362527 A1 CA2362527 A1 CA 2362527A1 CA 002362527 A CA002362527 A CA 002362527A CA 2362527 A CA2362527 A CA 2362527A CA 2362527 A1 CA2362527 A1 CA 2362527A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- nucleic acid
- prostate cancer
- antibody
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/85—Reproductive organs or embryos
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Abstract
Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences.
Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.
Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.
Claims (35)
1. An isolated nucleic acid segment comprising a full length sequence or the full length complement of a sequence selected from the group consisting of SEQ ID
NO:1, SEQ ID NO:3 and SEQ ID NO:4.
NO:1, SEQ ID NO:3 and SEQ ID NO:4.
2. An isolated nucleic acid molecule of a size between about 14 and 100 bases in length, identical in sequence to a contiguous portion of at least 14 bases of a nucleic acid or its complement selected from the group consisting of SEQ ID NO:3 and SEQ
ID NO:4.
ID NO:4.
3. The isolated nucleic acid molecule of claim 2, of a size of between about and 100 bases in length.
4. The isolated nucleic acid molecule of claim 2, of a size of between about and 100 bases in length.
5. The isolated nucleic acid molecule of claim 2, of a size of between about and 100 bases in length.
6. The isolated nucleic acid molecule of claim 2, of a size of between about and 100 bases in length.
7. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ
ID NO:1.
ID NO:1.
8. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ
ID NO:3.
ID NO:3.
9. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ
ID NO:4.
ID NO:4.
10. An isolated nucleic acid encoding a full length amino acid sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:5.
11. An isolated polypeptide comprising a full length amino acid sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:5.
12. An isolated peptide of a size between 10 and 25 amino acids in length, identical in sequence to a contiguous portion of at least 10 amino acid residues of SEQ ID NO:4.
13. An isolated peptide of a size between 10 and 65 amino acids in length, identical in sequence to a contiguous portion of at least 10 amino acid residues of SEQ ID NO:5.
14. A method for detecting prostate cancer cells in a biological sample comprising the step of detecting a prostate cancer marker in said sample, wherein said prostate cancer marker is a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.
15. The method of claim 14, further comprising the steps of a) amplifying nucleic acids from said sample to form nucleic acid amplification products;
b) contacting said nucleic acid amplification products with an oligonucleotide probe that will hybridize under stringent conditions with said prostate cancer marker;
c) detecting the nucleic acid amplification products which hybridize with said probe; and d) measuring the amount of said nucleic acid amplification products that hybridize with said probe, wherein an increased amount of said prostate cancer marker in said sample, relative to the amount of said marker in normal tissue samples, is indicative of the prostate cancer cells.
b) contacting said nucleic acid amplification products with an oligonucleotide probe that will hybridize under stringent conditions with said prostate cancer marker;
c) detecting the nucleic acid amplification products which hybridize with said probe; and d) measuring the amount of said nucleic acid amplification products that hybridize with said probe, wherein an increased amount of said prostate cancer marker in said sample, relative to the amount of said marker in normal tissue samples, is indicative of the prostate cancer cells.
16. The method of claim 15, in which said oligonucleotide probe is selected to bind specifically to an isolated nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.
17. The method of claim 14, further comprising the steps of a) providing primers that will selectively amplify said prostate cancer marker;
b) amplifying said nucleic acids with said primers to form nucleic acid amplification products;
c) detecting said nucleic acid amplification products; and d) quantifying said nucleic acid amplification products, wherein an increased amount of said prostate cancer marker in said sample, relative to the amount of said marker in normal tissue samples, is indicative of the prostate cancer cells.
b) amplifying said nucleic acids with said primers to form nucleic acid amplification products;
c) detecting said nucleic acid amplification products; and d) quantifying said nucleic acid amplification products, wherein an increased amount of said prostate cancer marker in said sample, relative to the amount of said marker in normal tissue samples, is indicative of the prostate cancer cells.
18. The method of claim 17, wherein said primers are selected to amplify a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.
19. The method of claim 16, further comprising determining the prognosis of prostate cancer patients by quantifying the nucleic acid amplification product binding to a probe specific for said prostate cancer marker.
20. The method of claim 16, further comprising determining the diagnosis of human prostate cancer by quantifying the nucleic acid amplification product binding to a probe specific for said prostate cancer marker.
21. The method of claim 18, further comprising determining the prognosis of prostate cancer patients by quantifying the nucleic acid amplification product.
22. The method of claim 18, further comprising determining the diagnosis of human prostate cancer by quantifying the nucleic acid amplification product.
23. A method of treating individuals with prostate cancer, comprising the steps of:
a) obtaining a sample of tissue from an individual with prostate cancer;
b) screening said sample for the expression of a polypeptide comprising SEQ ID NO:2;
c) providing an antibody that reacts immunologically against said polypeptide; and d) administering an effective amount of said antibody to an individual with prostate cancer.
a) obtaining a sample of tissue from an individual with prostate cancer;
b) screening said sample for the expression of a polypeptide comprising SEQ ID NO:2;
c) providing an antibody that reacts immunologically against said polypeptide; and d) administering an effective amount of said antibody to an individual with prostate cancer.
24. A method of treating individuals with prostate cancer, comprising the steps of:
a) obtaining a sample of tissue from an individual with prostate cancer;
b) screening said sample for the expression of a polynucleotide comprising SEQ ID NO:1;
c) providing an antisense DNA molecule that encodes an RNA molecule that binds to said polynucleotide;
d) providing said antisense DNA molecule in the form of a human vector containing appropriate regulatory elements for the production of said RNA molecule; and e) administering an effective amount of said vector to an individual with prostate cancer.
a) obtaining a sample of tissue from an individual with prostate cancer;
b) screening said sample for the expression of a polynucleotide comprising SEQ ID NO:1;
c) providing an antisense DNA molecule that encodes an RNA molecule that binds to said polynucleotide;
d) providing said antisense DNA molecule in the form of a human vector containing appropriate regulatory elements for the production of said RNA molecule; and e) administering an effective amount of said vector to an individual with prostate cancer.
25. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) a primer pair for amplifying a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID
NO:4; and (b) containers for each of said primers.
(a) a primer pair for amplifying a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID
NO:4; and (b) containers for each of said primers.
26. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) an oligonucleotide probe which binds under high stringency conditions to an isolated nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4; and (b) a container for said probe.
(a) an oligonucleotide probe which binds under high stringency conditions to an isolated nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4; and (b) a container for said probe.
27. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) an antibody which binds immunologically to a polypeptide comprising SEQ ID NO:5; and (b) a container for said antibody.
(a) an antibody which binds immunologically to a polypeptide comprising SEQ ID NO:5; and (b) a container for said antibody.
28. A method for detecting prostate cancer cells in biological samples, comprising the following steps:
(a) providing an antibody that binds immunologically to a peptide comprising SEQ ID NO:5;
(b) contacting a human tissue sample with said antibody;
(c) separating antibody bound to said tissue sample from unbound antibody; and (d) detecting the bound antibody.
(a) providing an antibody that binds immunologically to a peptide comprising SEQ ID NO:5;
(b) contacting a human tissue sample with said antibody;
(c) separating antibody bound to said tissue sample from unbound antibody; and (d) detecting the bound antibody.
29. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) an antibody which binds immunologically to a polypeptide comprising an amino acid sequence selected from SEQ ID NO:5; and (b) a container for said antibody.
(a) an antibody which binds immunologically to a polypeptide comprising an amino acid sequence selected from SEQ ID NO:5; and (b) a container for said antibody.
30. A method for treating individuals with prostate cancer, comprising the following steps:
(a) selecting a polypeptide comprising a sequence selected from SEQ ID
NO:5;
(b) providing an inhibitor designed to bind specifically to said polypeptide;
and (c) administering an effective dosage of said inhibitor to a prostate cancer patient.
(a) selecting a polypeptide comprising a sequence selected from SEQ ID
NO:5;
(b) providing an inhibitor designed to bind specifically to said polypeptide;
and (c) administering an effective dosage of said inhibitor to a prostate cancer patient.
31. The isolated nucleic acid according to claim 1, wherein said nucleic acid is incorporated into a human expression vector.
32. The isolated nucleic acid according to claim 10, wherein said nucleic acid is incorporated into a human expression vector.
33. The method of claim 24, wherein said antisense DNA molecule encodes a full length complementary sequence to SEQ ID NO:1.
34. The method of claim 23, wherein said antibody is in the form of a single-chain antibody.
35. The method of claim 34, wherein said administering step comprises providing an expression vector that encodes said single-chain antibody.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/247,188 | 1999-02-09 | ||
US09/247,188 US6156515A (en) | 1999-02-09 | 1999-02-09 | Prostate-specific gene for diagnosis, prognosis and management of prostate cancer |
PCT/US2000/002052 WO2000047773A1 (en) | 1999-02-09 | 2000-01-24 | A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2362527A1 true CA2362527A1 (en) | 2000-08-17 |
CA2362527C CA2362527C (en) | 2011-07-12 |
Family
ID=22933947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2362527A Expired - Fee Related CA2362527C (en) | 1999-02-09 | 2000-01-24 | A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer |
Country Status (8)
Country | Link |
---|---|
US (6) | US6156515A (en) |
EP (2) | EP1734134B1 (en) |
AT (1) | ATE329057T1 (en) |
AU (1) | AU2740100A (en) |
CA (1) | CA2362527C (en) |
DE (1) | DE60028544T2 (en) |
ES (1) | ES2394093T3 (en) |
WO (1) | WO2000047773A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008110006A1 (en) * | 2007-03-12 | 2008-09-18 | Miraculins Inc. | Biomarkers of prostate cancer and uses thereof |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6156515A (en) | 1999-02-09 | 2000-12-05 | Urocor, Inc. | Prostate-specific gene for diagnosis, prognosis and management of prostate cancer |
GB9912965D0 (en) * | 1999-06-03 | 1999-08-04 | Oxford Biomedica Ltd | In vivo selection method |
EP1344064A2 (en) * | 2000-11-01 | 2003-09-17 | Diadexus, Inc. | Compositions and methods relating to prostate specific genes and proteins |
AU2002236579A1 (en) * | 2000-11-06 | 2002-05-21 | Diadexus, Inc. | Compositions and methods relating to prostate specific genes and proteins |
WO2002038810A2 (en) * | 2000-11-06 | 2002-05-16 | Diadexus, Inc. | Compositions and methods relating to prostate specific genes and proteins |
AU2002217991A1 (en) * | 2000-11-21 | 2002-06-03 | Diadexus, Inc. | Compositions and methods relating to prostate specific genes and proteins |
GB0119852D0 (en) * | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
AU2002324902A1 (en) * | 2001-09-06 | 2003-03-24 | The Burnham Institute | Serine/threonine hydrolase proteins and screening assays |
AU2002360305A1 (en) * | 2001-10-26 | 2003-05-06 | Immunivest Corporation | Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample |
US20050069889A1 (en) * | 2001-12-21 | 2005-03-31 | Naoki Nihei | Novel metastasis suppressor gene on human chromosome 8 |
US7534580B2 (en) * | 2002-05-01 | 2009-05-19 | Ambrilia Biopharma Inc. | PSP94 diagnostic reagents and assays |
US7713693B1 (en) | 2004-09-01 | 2010-05-11 | University Of Louisiana At Monroe | Human cancer cell specific gene transcript |
US20070029205A1 (en) * | 2005-08-08 | 2007-02-08 | Shoou-Aaey Chen | Method of surface treatment for metal and nonmetal surfaces |
US20100294681A1 (en) * | 2007-06-05 | 2010-11-25 | Dylina Tim J | Golf bag |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US20130190321A1 (en) * | 2012-01-23 | 2013-07-25 | West Chester University Of Pennsylvania | Methods and compositions relating to proliferative disorders of the prostate |
US9977033B2 (en) | 2012-09-11 | 2018-05-22 | The Board Of Regents Of The University Of Texas System | Methods for assessing cancer recurrence |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4215051A (en) * | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4883750A (en) * | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
WO1987000880A1 (en) * | 1985-08-09 | 1987-02-12 | Soederstroem Gert | Safety device |
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
AU622104B2 (en) * | 1987-03-11 | 1992-04-02 | Sangtec Molecular Diagnostics Ab | Method of assaying of nucleic acids, a reagent combination and kit therefore |
IL86724A (en) * | 1987-06-19 | 1995-01-24 | Siska Diagnostics Inc | Method and kits for the amplification and detection of nucleic acid sequences |
WO1989001025A2 (en) * | 1987-07-24 | 1989-02-09 | Allrutan Bio-Produkte Gmbh | Foodstuffs, dietetic foodstuffs, foodstuff additives, cosmetics and drugs based on yeast |
CA1323293C (en) * | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
WO1989006700A1 (en) * | 1988-01-21 | 1989-07-27 | Genentech, Inc. | Amplification and detection of nucleic acid sequences |
CA1340807C (en) * | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
US4932207A (en) * | 1988-12-28 | 1990-06-12 | Sundstrand Corporation | Segmented seal plate for a turbine engine |
DK0517895T3 (en) * | 1990-12-14 | 1997-04-07 | Univ California | Chimeric chains for receptor-linked signal transduction pathways |
US5262311A (en) * | 1992-03-11 | 1993-11-16 | Dana-Farber Cancer Institute, Inc. | Methods to clone polyA mRNA |
ATE231920T1 (en) * | 1992-03-11 | 2003-02-15 | Dana Farber Cancer Inst Inc | METHOD TO CLONE MRNA |
DE69332642T2 (en) * | 1992-10-29 | 2003-10-02 | Thomas Jefferson University Ph | METHODS FOR DETECTING MICROMETASAS IN PROSTATE CANCER |
US5279721A (en) | 1993-04-22 | 1994-01-18 | Peter Schmid | Apparatus and method for an automated electrophoresis system |
US5639656A (en) * | 1994-03-31 | 1997-06-17 | Medical College Of Hampton Road | Antibodies reactive with biological markers of benign prostate hyperplasia |
US5658730A (en) * | 1994-12-23 | 1997-08-19 | Ctrc Research Foundation | Methods of human prostate cancer diagnosis |
JPH10513044A (en) * | 1995-01-20 | 1998-12-15 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | Human prostate specific reductase |
US5633161A (en) * | 1995-03-29 | 1997-05-27 | Millennium Pharmaceuticals, Inc. | Murine gene fomy030 coding for tumor progression inhibitor |
US6218529B1 (en) * | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
EP0951541B1 (en) * | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
WO1999037811A1 (en) * | 1998-01-21 | 1999-07-29 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US6476207B1 (en) * | 1998-06-11 | 2002-11-05 | Chiron Corporation | Genes and gene expression products that are differentially regulated in prostate cancer |
US6156515A (en) | 1999-02-09 | 2000-12-05 | Urocor, Inc. | Prostate-specific gene for diagnosis, prognosis and management of prostate cancer |
US8067152B2 (en) * | 2006-02-27 | 2011-11-29 | The Fred Hutchinson Cancer Research Center | Liver cancer biomarkers |
US8312249B1 (en) | 2008-10-10 | 2012-11-13 | Apple Inc. | Dynamic trampoline and structured code generation in a signed code environment |
FR2957821B1 (en) | 2010-03-24 | 2014-08-29 | Inst Francais Du Petrole | NEW AREA OF CATALYST REGENERATION DIVIDED IN SECTORS FOR REGENERATIVE CATALYTIC UNITS |
-
1999
- 1999-02-09 US US09/247,188 patent/US6156515A/en not_active Expired - Lifetime
-
2000
- 2000-01-24 EP EP06011686A patent/EP1734134B1/en not_active Expired - Lifetime
- 2000-01-24 ES ES06011686T patent/ES2394093T3/en not_active Expired - Lifetime
- 2000-01-24 CA CA2362527A patent/CA2362527C/en not_active Expired - Fee Related
- 2000-01-24 WO PCT/US2000/002052 patent/WO2000047773A1/en active IP Right Grant
- 2000-01-24 AT AT00905770T patent/ATE329057T1/en not_active IP Right Cessation
- 2000-01-24 EP EP00905770A patent/EP1151140B9/en not_active Expired - Lifetime
- 2000-01-24 AU AU27401/00A patent/AU2740100A/en not_active Abandoned
- 2000-01-24 DE DE60028544T patent/DE60028544T2/en not_active Expired - Lifetime
- 2000-05-24 US US09/579,236 patent/US6369195B1/en not_active Expired - Fee Related
-
2001
- 2001-01-02 US US09/754,016 patent/US20020068281A1/en not_active Abandoned
- 2001-09-25 US US09/962,902 patent/US20030017472A1/en not_active Abandoned
-
2007
- 2007-02-12 US US11/706,417 patent/US7993830B2/en not_active Expired - Fee Related
-
2011
- 2011-06-10 US US13/157,691 patent/US20110286917A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008110006A1 (en) * | 2007-03-12 | 2008-09-18 | Miraculins Inc. | Biomarkers of prostate cancer and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1734134B1 (en) | 2012-08-29 |
US6369195B1 (en) | 2002-04-09 |
EP1151140B9 (en) | 2007-01-10 |
EP1734134A2 (en) | 2006-12-20 |
US20080044416A1 (en) | 2008-02-21 |
EP1151140A1 (en) | 2001-11-07 |
DE60028544D1 (en) | 2006-07-20 |
DE60028544T2 (en) | 2007-06-06 |
US20110286917A1 (en) | 2011-11-24 |
US7993830B2 (en) | 2011-08-09 |
WO2000047773A1 (en) | 2000-08-17 |
ES2394093T3 (en) | 2013-01-17 |
US20020068281A1 (en) | 2002-06-06 |
AU2740100A (en) | 2000-08-29 |
US20030017472A1 (en) | 2003-01-23 |
US6156515A (en) | 2000-12-05 |
EP1151140B1 (en) | 2006-06-07 |
ATE329057T1 (en) | 2006-06-15 |
CA2362527C (en) | 2011-07-12 |
EP1151140A4 (en) | 2002-12-18 |
EP1734134A3 (en) | 2007-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2362527A1 (en) | A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer | |
CA2262403A1 (en) | Biomarkers and targets for diagnosis, prognosis and management of prostate disease | |
KR101446626B1 (en) | Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient | |
RU2721916C2 (en) | Methods for prostate cancer prediction | |
CA2269634A1 (en) | Reagents and methods useful for detecting diseases of the breast | |
CA2318354A1 (en) | Biomarkers and targets for diagnosis, prognosis and management of prostate disease | |
CA2488404A1 (en) | Genes and polypeptides relating to human colon cancers | |
JP2004528810A5 (en) | ||
CA2380550A1 (en) | C type lectin transmembrane antigen expressed in human prostate cancer and uses thereof | |
AU2014373927B2 (en) | Prostate cancer gene profiles and methods of using the same | |
JP2010508855A5 (en) | ||
JP2003508022A5 (en) | ||
CA2418422A1 (en) | Novel kallikrein gene | |
KR20180028028A (en) | Composition and method for improving sensitivity and specificity on detection of nucleic acids with using dCas9 protein and gRNA for binding to target nucleic acid sequence | |
CA2263895A1 (en) | Therapeutic and diagnostic applications of perlecan domain i splice variants | |
JP2009523004A5 (en) | ||
KR20020007362A (en) | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use | |
CA2287571A1 (en) | Reagents and methods useful for detecting diseases of the prostate | |
CA2232237A1 (en) | Reagents and methods useful for detecting diseases of the breast | |
JPH08500731A (en) | Diagnostic method | |
JP2000500650A (en) | Detection of breast cancer virus-like sequences in human breast cancer | |
JP4344165B2 (en) | Keloid diagnosis method | |
US6379951B1 (en) | Compounds for immunotherapy of breast cancer and methods for their use | |
JP2005052061A (en) | Method for detecting target nucleic acid using zinc finger protein | |
KR101683961B1 (en) | Recurrence Marker for Diagnosis of Bladder Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20160125 |